Uncompromised Quality and Robust Scalability for Biopharmaceutical Cell Line Development
Development of new protein therapeutics is a complex process, with technical and regulatory hurdles to overcome in the path to commercial success. With increasing competition and the progress of biosimilars, drug developers need to focus on speed, predictability, and quality.
The Sartorius CHO Platform service package brings together cell line development (CLD) including the fully optimized 4Cell® cell culture media system, protein characterization, cell banking, and biosafety testing to accelerate your program and puts your molecule on the path to success.
The package offers reduced costs and proven results while maintaining an exceptional degree of flexibility. With the freedom to use the CMO of your choice, you can rapidly progress from DNA to GMP cell bank (MCB | WCB) and overcome typical obstacles that can delay a first commercial manufacturing batch.